Live from International Antiviral Society–USA (IAS–USA)
One monoclonal antibody is good, two is better.
One monoclonal antibody is good, two is better.
Live from International Antiviral Society–USA (IAS–USA)
Dr. Jonathan Li: Mutations occur between the areas where antibodies bind to virus and the spike protein.
Dr. Jonathan Li: Mutations occur between the areas where antibodies bind to virus and the spike protein.
Live from International Antiviral Society–USA (IAS–USA) @DrJLi is talking about variants. Vaccines appears to protect against the B.1.1.7 variant (originally found in the UK) as well as the original virus.
Live from International Antiviral Society–USA (IAS–USA) @DrJLi says @modernatx and @pfizer vaccines "should still give you excellent protection, especially against severe disease" from variants.
@DrJLi notes that the FDA-authorized vaccines still have good protection even against hard-to-neutralize variants. Plus, boosters are on the way.
How concerned should we be about home-grown variants in the US? @DrJLi says the California variant has become dominant. The variant in NY makes up 40% of coronavirus infections there.
How do coronavirus variants affect efficacy of monoclonal antibodies? California variant has a resistance gene against a monoclonal antibody. Company limiting distribution of one monoclonal antibody because of this.
@DrJLi says rise of variants suggests people with B-cell cancers may have longer infections that allow variants to form.
@drjli: Variants are scary. But infections are going down in places where variants are circulating. "What this shows is that social distancing and masks work... What worked against the old variants will work against new variants."
I missed the first half of this great webinar from @drjli because I was doing an interview, but I'm hoping there's a replay. "There are tons of variants out there, but not every variants gets a name. You have to be special to get a name."
LIVE: @drjli is headlining an IAS–USA webinar, "Fighting a Moving Target: SARS-CoV-2 Variants and Viral Escape."
He notes some good news about B.1.1.7. It is more infectious, but monoclonal antibody bamlanivimab still works against it.
He notes some good news about B.1.1.7. It is more infectious, but monoclonal antibody bamlanivimab still works against it.
LIVE: @drjli is taking questions at an IAS–USA webinar on variants.
Every respiratory virus does better in one season or another. Viruses tend to last longer in colder temperatures. Was last summer's drop in infections due to this? Or due to more outdoor activity? Who knows?
Every respiratory virus does better in one season or another. Viruses tend to last longer in colder temperatures. Was last summer's drop in infections due to this? Or due to more outdoor activity? Who knows?
LIVE: @drjli is taking questions at an IAS–USA webinar on variants.
Are patients w/ advanced HIV at high risk from covid? The risk seems to be in B-cell diseases (lymphoma), whereas ppl w/ advanced HIV have T-cell problems. Combination drug therapy prevents T-cell issues.
Are patients w/ advanced HIV at high risk from covid? The risk seems to be in B-cell diseases (lymphoma), whereas ppl w/ advanced HIV have T-cell problems. Combination drug therapy prevents T-cell issues.
LIVE: @drjli is taking questions at an IAS–USA webinar on variants.
If coronaviruses don't mutate all that often, why so many variants now?
"When you have 100s of millions of people getting infected, you're giving that virus so many rolls of the dice."
If coronaviruses don't mutate all that often, why so many variants now?
"When you have 100s of millions of people getting infected, you're giving that virus so many rolls of the dice."
LIVE: @drjli is taking questions at an IAS–USA webinar on variants. Why use @astrazeneca vaccine? " In places where they don't have other vaccines, 70% efficacy is better than nothing."
• • •
Missing some Tweet in this thread? You can try to
force a refresh
